Naval vessel launched in B.C. is longest-ever built in Canadarich t 。

Interview: ONE OR EIGHT talks about their new music, working with Big Sean, and the digital ageSAN DIEGO , Dec. 13, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved CRENESSITYTM (crinecerfont) capsules and oral solution as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia (CAH), a rare, serious and lifelong genetic condition involving the adrenal glands. CRENESSITY, a potent and selective oral corticotropin-releasing factor type 1 receptor (CRF 1 ) antagonist, is the first and only classic CAH treatment that directly reduces excess adrenocorticotropic hormone (ACTH) and downstream adrenal androgen production, allowing for glucocorticoid dose reduction. It is a breakthrough in the treatment landscape for classic CAH. "For the last three decades, Neurocrine Biosciences, together with our late founder, Wylie W. Vale , has conducted groundbreaking research uncovering the critical role of corticotropin-releasing factor and its receptor, CRF 1 , in the pathophysiology of congenital adrenal hyperplasia," said Kyle W. Gano , Ph.D., Chief Executive Officer, Neurocrine Biosciences. "The approval of CRENESSITY is a significant milestone for the CAH community, and we are grateful to the individuals who participated in our clinical trials, including their families and caregivers, and to the clinical investigators who helped advance a new therapy and class of medicines." "Patients and families struggle to achieve balance between managing the symptoms of CAH and the side effects or complications of treatment with high-dose steroids, which may impact quality of life," said Dina Matos , Executive Director, CARES Foundation. "We are grateful to Neurocrine Biosciences for engaging with our community throughout the drug development process to understand our needs and ultimately providing this new medication that can help reduce excess adrenal androgens and the need for high-dose steroid treatment for individuals living with CAH." CRENESSITY is expected to be commercially available in approximately one week. The medication will be provided through PANTHERx Rare, a specialty pharmacy, to centralize and simplify CRENESSITY prescription fulfillment. Neurocrine Biosciences is committed to supporting patients in obtaining treatment with CRENESSITY by offering Neurocrine Access Support, a free, comprehensive assistance program created for patients, caregivers and healthcare providers. It offers a range of options to make sure patients have everything they need to begin and continue taking CRENESSITY. A dedicated Care Coordinator, backed by a team, is available to help patients and caregivers navigate the insurance process and identify appropriate financial assistance options. Most patients will pay $10 or less per month for CRENESSITY*. For more information, visit www.NBIaccess.com/crenessity or call 1-855-CRNSITY (276-7489) Monday-Friday 8 am-8 pm ET . *Additional terms and conditions apply. CAHtalyst TM Clinical Program Overview: The FDA approval is supported by the largest-ever clinical trial program of classic CAH, the CAHtalyst Pediatric and Adult Phase 3 global registrational studies. CAHtalyst Phase 3 data results in pediatric and adult patients with classic CAH were published in The New England Journal of Medicine . "The clinical results across both CAHtalyst studies support the efficacy and safety profile of CRENESSITY and its ability to reduce the overproduction of adrenal androgens, allowing for a meaningful reduction in glucocorticoid dosage, while maintaining or enhancing control of these androgens," said Richard Auchus , M.D., Ph.D., Professor, University of Michigan Health, Principal Investigator. "Chronic treatment with supraphysiologic glucocorticoids can cause a number of short- and long-term health consequences, such as obesity, hypertension and osteoporosis, so the ability for patients with CAH to lower their glucocorticoid dose to a more physiologic level can have profound benefits." In both CAHtalyst studies, CRENESSITY enabled lower steroid doses and decreased androgen levels. Phase 3 CAHtalyst Pediatric Study: Phase 3 CAHtalyst Adult Study: CRENESSITY was well tolerated with few treatment-related adverse events in both CAHtalyst studies. Pediatric and adult patients taking CRENESSITY had no treatment-related serious adverse events. Adrenal insufficiency and crisis are risks of living with CAH that CRENESSITY does not address and can occur when a patient's GC dose is too low. In the CAHtalyst Pediatric study, there were no cases of adrenal crisis among patients taking CRENESSITY or placebo. In the CAHtalyst Adult study, two patients (1.6%) taking CRENESSITY experienced adrenal crisis. No patients on placebo experienced adrenal crisis. However, one patient (1.7%) on placebo experienced adrenal insufficiency. Patients should work with their healthcare provider to manage GC dosing while taking CRENESSITY. For more information about CRENESSITY, visit Crenessity.com . About Congenital Adrenal Hyperplasia Congenital adrenal hyperplasia (CAH) is a rare genetic condition that results in an enzyme deficiency that alters the production of adrenal steroid hormones, such as cortisol, aldosterone and adrenal androgens, which are essential for life. Approximately 95% of CAH cases are caused by variants of the CYP21A2 gene that leads to deficiency of the enzyme 21-hydroxylase (21-OH). Severe deficiency of this enzyme leads to an inability of the adrenal glands to produce enough cortisol and, in approximately 75% of cases, aldosterone. Because individuals with CAH are still able to produce androgens, the unused precursors that would normally be used to make cortisol instead result in the production of excess amounts of androgens. If left untreated, CAH can result in salt wasting, dehydration and even death. Historically, exogenous glucocorticoids (GCs) have been used not only to correct the endogenous cortisol deficiency, but doses used are higher than cortisol replacement needed (supraphysiologic) to lower the levels of adrenocorticotropic hormone (ACTH) and adrenal androgens. However, GC treatment at high doses has been associated with serious and significant complications of steroid excess, including metabolic issues such as weight gain and diabetes, cardiovascular disease and osteoporosis. Additionally, long-term treatment with high-dose GCs may have psychological and cognitive impact, such as changes in mood and memory. Adrenal androgen excess has been associated with abnormal bone growth and development in pediatric patients, female health problems such as excess facial hair growth and menstrual irregularities, testicular rest tumors in males and fertility issues in both sexes. About The CAHtalystTM Studies The Phase 3 CAHtalystTM global registrational studies were designed to evaluate the safety, efficacy and tolerability of CRENESSITY in children and adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The CAHtalyst studies were the largest-ever clinical trial program in classic CAH, including 285 pediatric and adult patients. The CAHtalyst Pediatric study included 103 pediatric patients aged four to 17 years. The study tested two questions. The first question evaluated whether four weeks of CRENESSITY treatment could improve androgen control. The second question evaluated whether an additional 24 weeks of CRENESSITY treatment enabled customized glucocorticoid (GC) down-titration while androstenedione levels were maintained or improved. The CAHtalyst Adult study included 182 adult patients aged 18 to 58 years. Similarly, the first question of the study evaluated whether four weeks of CRENESSITY treatment could improve androgen control, and the second question evaluated whether an additional 20 weeks of CRENESSITY treatment enabled GC reduction to physiologic range while androstenedione levels were maintained or improved. Data from the CAHtalyst Phase 3 studies supported approval of CRENESSITY by the U.S. Food and Drug Administration in December 2024. The open-label extension treatment portions of both studies are ongoing. About CRENESSITYTM (crinecerfont) CRENESSITYTM is a potent and selective, oral corticotropin-releasing factor type 1 receptor (CRF 1 ) antagonist developed to reduce and control excess adrenocorticotropic hormone (ACTH) and adrenal androgens through a non-glucocorticoid (GC) mechanism for the treatment of classic congenital adrenal hyperplasia (CAH). Antagonism of CRF 1 receptors in the pituitary has been shown to decrease ACTH levels, which in turn decreases the production of adrenal androgens and potentially the symptoms associated with CAH. The robust clinical study data demonstrate that lowering adrenal androgen levels with CRENESSITY enables lower, more physiologic dosing of GCs to replace missing cortisol. CRENESSITY comes in capsules and an oral solution. The capsule formulation is available in 50 mg and 100 mg doses. The oral solution is available as a 50 mg/mL strength formulation. For adults 18 years and older, the recommended dosage is 100 mg twice daily taken orally with a meal. For pediatric patients four to 17 years of age weighing less than 55 kg (121 lbs), the recommended dosage is based on body weight and is administered twice daily, taken orally with a meal. For pediatric patients weighing more than 55 kg (121 lbs), the recommended dosage is 100 mg twice daily taken orally with a meal. Healthcare providers can work with patients to determine the appropriate formulation for use depending on patient needs. Patients receiving CRENESSITY should continue GC therapy for cortisol replacement. Important Information Approved Uses CRENESSITY (crinecerfont) is a prescription medicine used together with glucocorticoids (steroids) to control androgen (testosterone-like hormone) levels in adults and children 4 years of age and older with classic congenital adrenal hyperplasia (CAH). IMPORTANT SAFETY INFORMATION Do not take CRENESSITY if you: Are allergic to crinecerfont, or any of the ingredients in CRENESSITY. CRENESSITY may cause serious side effects, including : Allergic Reactions. Symptoms of an allergic reaction include tightness of the throat, trouble breathing or swallowing, swelling of the lips, tongue, or face, and rash. If you have an allergic reaction to CRENESSITY, get emergency medical help right away and stop taking CRENESSITY. Risk of Sudden Adrenal Insufficiency or Adrenal Crisis With Too Little Glucocorticoid (Steroid) Medicine. Sudden adrenal insufficiency or adrenal crisis can happen in people with congenital adrenal hyperplasia who are not taking enough glucocorticoid (steroid) medicine. You should continue taking your glucocorticoid (steroid) medicine during treatment with CRENESSITY. Certain conditions such as infection, severe injury, or shock may increase your risk for sudden adrenal insufficiency or adrenal crisis. Tell your healthcare provider if you get a severe injury, infection, illness, or have planned surgery during treatment. Your healthcare provider may need to change your dose of glucocorticoid (steroid) medicine. Before taking CRENESSITY, tell your healthcare provider about all of your medical conditions, including if you are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. Tell your healthcare provider about all the medicines you take , including prescription and over-the counter medicines, vitamins, and herbal supplements. The most common side effects of CRENESSITY in adults include tiredness, headache, dizziness, joint pain, back pain, decreased appetite, and muscle pain. The most common side effects of CRENESSITY in children include headache, stomach pain, tiredness, nasal congestion, and nose bleeds. These are not all the possible side effects of CRENESSITY. Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088. Dosage Forms and Strengths: CRENESSITY is available in 50 mg and 100 mg capsules and as an oral solution of 50 mg/mL. Please see full Prescribing Information About Neurocrine Biosciences, Inc. Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com , and follow the company on LinkedIn , X (formerly Twitter) and Facebook . (*in collaboration with AbbVie) The NEUROCRINE BIOSCIENCES Logo Lockup and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc. CRENESSITY and CAHtalyst are trademarks of Neurocrine Biosciences, Inc. Forward-Looking Statements In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the potential benefits to be derived from CRENESSITY for the treatment of classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency; the value and benefits CRENESSITY brings to patients with CAH; the ability of Neurocrine Biosciences to ensure patients have access to CRENESSITY; and whether the results from our clinical trials of CRENESSITY are indicative of real-world results. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following: risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, as well as risks and uncertainties associated with the commercialization of CRENESSITY; whether CRENESSITY receives adequate reimbursement from third-party payors; the degree and pace of market uptake of CRENESSITY; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY; risks associated with the Company's dependence on third parties for development and manufacturing activities related to CRENESSITY, and the ability of the Company to manage these third parties; risks that additional regulatory submissions for CRENESSITY or other product candidates may not occur or be submitted in a timely manner; risks that the FDA or other regulatory authorities may make adverse decisions regarding CRENESSITY; risks that post-approval CRENESSITY commitments or requirements may be delayed; risks that CRENESSITY may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY; and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission, including without limitation the Company's quarterly report on Form 10-Q for the quarter ended September 30, 2024 . Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than required by law. © 2024 Neurocrine Biosciences, Inc. All Rights Reserved. CP-CFT-US-0070 12/2024 View original content to download multimedia: https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-fda-approval-of-crenessity-crinecerfont-a-first-in-class-treatment-for-children-and-adults-with-classic-congenital-adrenal-hyperplasia-302331772.html SOURCE Neurocrine Biosciences, Inc. Best trending stories from the week. Success! An email has been sent to with a link to confirm list signup. Error! There was an error processing your request. You may occasionally receive promotions exclusive discounted subscription offers from the Roswell Daily Record. Feel free to cancel any time via the unsubscribe link in the newsletter you received. You can also control your newsletter options via your user dashboard by signing in.

Pep Guardiola spoke of his relief after Manchester City finally got back to winning ways with a comfortable 3-0 defeat of Nottingham Forest on Wednesday. The champions had descended into crisis after a run of seven games without a win – six of which were defeats and the other an embarrassing 3-3 draw after leading 3-0. Four of those losses had come in the Premier League, heavily damaging their chances of claiming a fifth successive title, but they appeared to turn the corner by sweeping Forest aside at the Etihad Stadium. “We needed it,” said City manager Guardiola. “The club, the players, everyone needed to win. “But it is just one game and in three days we are at Selhurst Park, where it has always been difficult. “We played good. We still conceded some transitions and missed some easy things and lost some passes that you have to avoid, but in general, the most important thing was to break this routine of not winning games and we won it.” Kevin De Bruyne, making his first start since September after overcoming a pelvic injury, made a huge difference to a side that appeared rejuvenated. His powerful header was turned in by Bernardo Silva for the opening goal and the Belgian followed up with a powerful strike to make it 2-0. The 33-year-old is out of contract at the end of the season but it was a strong riposte to recent suggestions of a rift with Guardiola. A sweet strike 💥 ⚡️ #HighSpeedMoments | @eAndGroup pic.twitter.com/WJOkfKo2zr — Manchester City (@ManCity) December 4, 2024 “I’m so happy for him,” said Guardiola of De Bruyne’s telling contribution. “Last season he was many months injured and this season as well. “I’m so happy he’s back. He fought a lot, he’s worked and he’s back with his physicality. The minutes he played in Anfield were really good and today he played 75 fantastic minutes.” Jeremy Doku wrapped up a pleasing win when he finished a rapid counter-attack just before the hour but there was still a downside for City with injuries to defenders Nathan Ake and Manuel Akanji. Guardiola said: “For Nathan it doesn’t look good and Manu has struggled a lot over the last two months. We will see. “Phil (Foden) has bronchitis but when he doesn’t have fever he will be ready.” Despite City’s dominance, Forest did have some bright moments and manager Nuno Espirito Santo was not downbeat. He said: “When you lose 3-0 and you say it was a good performance maybe people don’t understand, but I will not say that was a bad performance. “There are positive things for us in the game. Of course there are a lot of bad things, mistakes, but we had chances. “We didn’t achieve but I think we come out proud of ourselves because we tried. For sure, this game will allow us to grow.”The standard Lorem Ipsum passage, used since the 1500s "Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum." Section 1.10.32 of "de Finibus Bonorum et Malorum", written by Cicero in 45 BC "Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?" To keep reading, please log in to your account, create a free account, or simply fill out the form below.Skidding No. 10 Kansas hopes to get right vs. NC State

The rising price of paying the national debt is a risk for Trump's promises on growth and inflation WASHINGTON (AP) — Donald Trump has big plans for the economy. He also has big debt problem that'll be a hurdle to delivering on those plan. Trump has bold ambitions on tax cuts, tariffs and other programs. But high interest rates and the price of repaying the federal government’s existing debt could limit what he’s able to do. The federal debt stands at roughly $36 trillion, and the spike in inflation after the pandemic has pushed up the government’s borrowing costs such that debt service next year will easily exceed spending on national security. 'Wicked' and 'Gladiator' make gravity-defying theater debuts NEW YORK (AP) — “Wicked” and “Gladiator II” have debuted in theaters with a combined $270 million in ticket sales. Their worldwide performance breathed fresh life into global box office results that have struggled lately. Together the films turned the moviegoing weekend into one of the busiest of the year. Jon M. Chu’s lavish big-budget musical “Wicked,” starring Ariana Grande and Cynthia Erivo, debuted with $114 million domestically and $164.2 million globally. Ridley Scott’s “Gladiator II” is a sequel to his 2000 best picture-winning original and launched with $55.5 million in ticket sales. “Moana 2” is being released Wednesday, so it looks like Hollywood might be looking at historic sales over the Thanksgiving holiday. Trump's Republican Party is increasingly winning union voters. It's a shift seen in his labor pick WASHINGTON (AP) — Working-class voters helped Republicans make steady election gains this year and expanded a coalition that increasingly includes rank-and-file union members. It's a political shift spotlighting one of President-elect Donald Trump’s latest Cabinet picks: a GOP congresswoman, who has drawn labor support, to be his labor secretary. Oregon Rep. Lori Chavez-DeRemer narrowly lost her bid for a second term this month, despite strong backing from union members. They're a key part of the Democratic base but are gravitating in the Trump era toward a Republican Party traditionally allied with business interests. Trump raced to pick many Cabinet posts. He took more time to settle on a treasury secretary WASHINGTON (AP) — President-elect Donald Trump launched a blitz of picks for his Cabinet, but he took his time settling on billionaire investor Scott Bessent as his choice for treasury secretary. The Republican not only wanted someone who jibes with him, but an official who can execute his economic vision and look straight out of central casting while doing so. With his Yale University education and pedigree trading for Soros Fund Management before establishing his own funds, Bessent will be tasked with a delicate balancing act. Trump expects him to help reset the global trade order, enable trillions of dollars in tax cuts, ensure inflation stays in check, manage a ballooning national debt and still keep the financial markets confident. Trump chooses Bessent to be treasury secretary, Vought as budget chief, Chavez-DeRemer for Labor WASHINGTON (AP) — President-elect Donald Trump has chosen hedge fund manager Scott Bessent, an advocate for deficit reduction, to serve as his next treasury secretary. Bessent, 62, is founder of hedge fund Key Square Capital Management. He previously had worked on and off for Soros Fund Management since 1991. Trump also said he would nominate Russell Vought, 48, to lead the Office of Management and Budget, a position he held during Trump's first term. And Trump chose Rep. Lori Chavez-DeRemer, an Oregon Republican, as his labor secretary, and Scott Turner, a former football player who worked in Trump’s first administration, as his housing secretary. Afraid of losing the US-Canada trade pact, Mexico alters its laws and removes Chinese parts MEXICO CITY (AP) — Mexico has been taking a bashing for allegedly serving as a conduit for Chinese parts and products into North America. Officials here are terrified that a re-elected Donald Trump or politically struggling Justin Trudeau could simply expel their country from the U.S.-Mexico-Canada free trade agreement. Mexico's ruling Morena party is so afraid its has gone on a campaign to get companies to replace Chinese parts with locally made ones. And its legislators are consciously tweaking the wording of major laws to try to make them compatible with the trade pact's language. Mexico hopes the rules of the trade pact would prevent the U.S. or Canada from simply walking away. Australia withdraws a misinformation bill after critics compare it to censorship CANBERRA, Australia (AP) — Australia’s government has withdrawn a bill that would give a media watchdog power to monitor digital platforms and require them to keep records about misinformation and disinformation on their networks. Communications Minister Michelle Rowland said Sunday that the government was unable to drum up the support needed to pass the legislation. The opposition spokesman, David Coleman, said the bill “betrayed our democracy” and amounted to “censorship laws in Australia.” The bill would have granted the Australian Communications and Media Authority power over digital platforms by approving an enforceable code of conduct or standards for social media companies if self-regulation fell short. He'll be the last meatpacker in the Meatpacking District. Here's how NYC's gritty 'hood got chic NEW YORK (AP) — The last meatpackers in New York's Meatpacking District have agreed to end their leases early and make way for development on their city-owned lot. A third-generation meatpacker says he is ready to retire and he'll be proud to be there when the building closes. The closure date has not been set, but will mark the end of over a century of industrial life in the Meatpacking District. Starting in the 1970s, a new nightlife scene emerged as bars and nightclubs moved in. Today it's a hub for shopping, tourism, and recreation and only echoes of that grit remain. US budget airlines are struggling. Will pursuing premium passengers solve their problems? DALLAS (AP) — Delta and United Airlines have become the most profitable U.S. airlines by targeting premium customers while also winning a significant share of budget travelers. That is squeezing smaller low-fare carriers like Spirit Airlines, which filed for bankruptcy protection on Monday. Some travel industry experts think Spirit’s troubles indicate less-wealthy passengers will have fewer choices and higher prices. Other discount airlines are on better financial footing but also are lagging far behind the full-service airlines when it comes to recovering from the COVID-19 pandemic. Most industry experts think Frontier and other so-called ultra-low-cost carriers will fill the vacuum if Spirit shrinks, and that there's still plenty of competition to prevent prices from spiking. What to know about Scott Bessent, Trump's pick for treasury secretary WASHINGTON (AP) — President-elect Donald Trump has chosen money manager Scott Bessent, an advocate for deficit reduction and deregulation, to serve as his next treasury secretary. Bessent is a past supporter of Democrats who has become an enthusiastic supporter of Trump. He’s an advocate of cutting spending while extending the tax cuts approved by Congress in Trump’s first term. He has said tariffs imposed during a second Trump administration would be directed primarily at China.De'Vondre Campbell's mid-game quitting overshadowed the 49ers' offensive woes

One of the best Humble Bundles of 2024 is up for grabs right now. The Disney Classics: Black Friday Bundle includes 17 classic games for only $10 . It's an especially great bundle if you love Star Wars, LucasArts point-and-click adventures, and Lego games. All told, you're getting 10 Star Wars games, including a pair of Lego gems and both of BioWare's heralded Knights of the Old Republic RPGs. Three other Lego games are featured in the bundle, including both Lego Indiana Jones titles. Oh, and you're getting three of the best point-and-click adventure games of all time. Not only are you getting a bunch of great PC games for cheap, you're supporting a good cause. Proceeds from the bundle help Starlight Children's Foundation, a nonprofit that donates video games, VR headsets, toys, and other fun items to over hospitalized children at hundreds of hospitals across the United States and Canada. As usual, you can modify your donation to give more or less to the charity, developer, and Humble. That's a terrific selection of games, especially for fans of classic Star Wars and Lego games. With Indiana Jones and the Great Circle releasing next week--or this Friday if you preorder one of the pricier editions --it's the perfect time to revisit Indy's Lego adventures. Traveller's Tales released Lego Indiana Jones: The Original Adventures in 2008 and followed it up with a sequel in 2010. Both of these family-friendly games are a ton of fun whether you're adventuring solo or hunting for artifacts together with another player. The Original Adventures has story beats from the first three Indiana Jones films. The sequel was inspired by The Kingdom of the Crystal Skull. Both games include over 60 playable characters. There's a nice variety of genres represented in this batch of Star Wars games, including two of the most beloved games in franchise history: the 2003 role-playing game Star Wars: Knights of the Old Republic and its 2004 sequel, The Sith Lords. While these games are rough around the edges these days, all fans of BioWare games and Star Wars should give them a shot, as they are still satisfying 30-plus-hour adventures with fun, round-based combat systems and engrossing narratives. Another highlight here is Star Wars: Galactic Battlegrounds, a strategy game that is essentially Age of Empires 2 with Star Wars units and locations. The core gameplay of gathering resources, researching new technologies, and progressing through the ages remains the same, but instead of Scottish or Byzantine civilizations, you get to take control of Trade Federation, Galactic Empire, and Gungan forces. There are several more civilizations here, but if you're looking for classic real-time strategy that explores major conflicts across the prequel and original Star Wars trilogies, this is a fun game. For something more action-packed, Star Wars: The Force Unleashed is still a blast of fun. Released in the late 2000s, The Force Unleashed told the story of Darth Vader's secret apprentice and the rise of the Rebel Alliance. This was a hidden history of Star Wars that had never been explored before--and was rendered non-canon following Disney's purchase of Star Wars in the 2010s--allowing for a cinematic adventure that lived up to its name. This is the Ultimate Sith Edition as well, so in addition to the main campaign, there's some very cool DLC here that pits two of the strongest Force-wielders of their time against each other. The other Star Wars games available in this bundle include Jedi Academy--a sequel to Star Wars Jedi Knight 2: Jedi Outcast--more strategy games in the form of Star Wars: Rebellion and Empire at War, the fun first-person shooter Republic Commando, and two Lego Star Wars games: The Clone Wars and The Complete Saga. A few more bundle deals are also available right now from Humble, including a collection of cool sci-fi shooters , a selection of indie game publisher's Raw Fury's greatest hits , and several story-driven adventures from Telltale Games . You can also sign up for Humble Choice this month and grab eight new games, including Bomb Rush Cyberfunk, The Invincible, and several others. Humble Choice: December 2024 -- 8 games for $12 Sci-Fi Shooters Bundle -- 8 items for $19 The Telltale Collection -- 8 items for $12 Raw Fury: Rawcember to Remember Bundle -- 14 items for $15 If you still need to preorder a copy of Indiana Jones and the Great Circle, check out GameSpot's preorder guide for details on the three different editions, preorder bonuses, and more. And if all of these Indiana Jones games compel you to revisit the films, there are some great deals on box sets and 4K Blu-ray editions of Indy's best adventures.

AI misuseJAMESTOWN — The Ellendale Cardinals led the entire way in a comfortable 68-18 win over Warwick High School on Friday, Dec. 13, at the Jamestown Civic Center Center. The Cardinals (2-2) opened the scoring early in the first quarter taking a 2–0 and pushed it to 4-0 before a three from the Lady Warriors’ Isabella Baier trimmed the deficit to 4-3. That was close as the game was throughout the remainder of the frame as the Cardinals took a 16-5 lead into the second quarter. ADVERTISEMENT The Warriors (0-4) ended the Cardinals' run midway through the second quarter with a jumper to bring it closer at 21-7 but the Cardinals were able to keep it up from there getting a 30-10 lead into the break. In the opening half, the Lady Warriors were led by Baer’s six points while the Cardinals' scoring leader was Macy Norton with 10 points. The Lady Warriors put up a fight in the third quarter drawing multiple fouls as the Cardinals went into the third quarter up 55-18. In the frame, the Cardinals' Macy Norton led her team with seven points. The Cardinals shut out the Warriors in the fourth quarter outscoring them 13-0. The Cardinals' leading scorer in the win was Macy Norton with 17 points. The Lady Warriors leading scorer was Chayanne Touche who had 10 points. The Cardinals return to the floor at 7:30 p.m. on Tuesday, Dec. 17, when they go to LaMoure/Litchville-Marion. The Warriors look to get their first win of the season at 1 p.m. on Saturday, Dec. 14, when they take on Napoleon/Gackle-Streeter. EHS 68, WHS 18 ADVERTISEMENT EHS: 16 14 25 13–68 WHS: 5 5 8 0–18Georgia prison reforms get Senate committee backingStocks closed higher on Wall Street as the market posted its fifth straight gain and the Dow Jones notched another record high. The S&P 500 rose 0.3 per cent. The benchmark index’s 1.7 per cent gain for the week erased most of its loss from last week. Wall Street has steadied after a volatile few weeks. Credit: AP The Dow rose 1 per cent as it nudged past its most recent high set last week, and the Nasdaq composite rose 0.2 per cent. The Australian sharemarket is set to climb, with futures pointing to a rise of 52 points, or 0.6 per cent. Markets have been volatile over the last few weeks, losing ground in the runup to elections in November, then surging following Donald Trump’s victory, before falling again. The S&P 500 has been steadily rising throughout this week to within close range of its record. It’s now within about 0.5 per cent of its all-time high set last week. “Overall, market behaviour has normalised following an intense few weeks,” said Mark Hackett, chief of investment research at Nationwide, in a statement. Several retailers jumped after giving Wall Street encouraging financial updates. Gap soared 12.8 per cent after handily beating analysts’ third-quarter earnings and revenue expectations, while raising its own revenue forecast for the year. Discount retailer Ross Stores rose 2.2 per cent after raising its earnings forecast for the year. EchoStar fell 2.8 per cent after DirecTV called off its purchase of that company’s Dish Network unit. Smaller company stocks had some of the biggest gains. The Russell 2000 index rose 1.8 per cent. A majority of stocks in the S&P 500 gained ground, but those gains were kept in check by slumps for several big technology companies. Nvidia fell 3.2 per cent. Its pricey valuation makes it among the heaviest influences on whether the broader market gains or loses ground. The company has grown into a nearly $US3.6 trillion ($5.5 trillion) behemoth because of demand for its chips used in artificial-intelligence technology. Intuit, which makes TurboTax and other accounting software, fell 5.7 per cent. It gave investors a quarterly earnings forecast that fell short of analysts’ expectations. Facebook owner Meta Platforms fell 0.7 per cent following a decision by the Supreme Court to allow a multibillion-dollar class action investors’ lawsuit to proceed against the company. It stems from the privacy scandal involving the Cambridge Analytica political consulting firm. All told, the S&P 500 rose 20.63 points to 5,969.34. The Dow climbed 426.16 points to 44,296.51, and the Nasdaq picked up 42.65 points to close at 2,406.67. European markets closed mostly higher and Asian markets ended mixed. Crude oil prices rose. Treasury yields held relatively steady in the bond market. The yield on the 10-year Treasury fell to 4.41 per cent from 4.42 per cent late Thursday. In the crypto market, bitcoin hovered around $US99,000, according to CoinDesk. It has more than doubled this year and first surpassed the $US99,000 level on Thursday. Retailers remained a big focus for investors this week amid close scrutiny on consumer spending habits headed into the holiday shopping season. Walmart, the nation’s largest retailer, reported a quarter of strong sales and gave investors an encouraging financial forecast. Target, though, reported weaker earnings than analysts’ expected and its forecast disappointed Wall Street. Consumer spending has fueled economic growth, despite a persistent squeeze from inflation and high borrowing costs. Inflation has been easing and the Federal Reserve has started trimming its benchmark interest rates. That is likely to help relieve pressure on consumers, but any major shift in spending could prompt the Fed to reassess its path ahead on interest rates. Also, any big reversals on the rate of inflation could curtail spending. Consumer sentiment remains strong, according to the University of Michigan’s consumer sentiment index. It revised its latest figure for November to 71.8 from an initial reading of 73 earlier this month, though economists expected a slight increase. It’s still up from 70.5 in October. The survey also showed that consumers’ inflation expectations for the year ahead fell slightly to 2.6 per cent, which is the lowest reading since December of 2020. Wall Street will get another update on how consumers feel when the business group The Conference Board releases its monthly consumer confidence survey on Tuesday. A key inflation update will come on Wednesday when the US releases its October personal consumption expenditures index. The PCE is the Fed’s preferred measure of inflation and this will be the last PCE reading prior to the central bank’s meeting in December. AP The Market Recap newsletter is a wrap of the day’s trading. Get it each we e kday afternoon .

As Wayanad job scam hits Congress party, police begins probe into the suicide cases

2024 FCS football playoff bracket: Predictions, picks for every FCS playoff game and round - NCAA.comRed-hot Devils seeking rare success against Predators

Eagles look to clinch NFC East title while Cowboys hope to play spoilerBaker Mayfield mocks Tommy DeVito's celebration as the Bucs embarrass the Giants 30-7

Grim reaper at the wheel; ex-wife's revenge; hand in a basket

AFRICA MUST BRIDGE THE DIGITAL DIVIDE